Genetic Engineering

Genetic Engineering
Generation of genetically-encoded sensors of neurotransmitter activity

Zeclinics R&D has extensive expertise in the use of CRISPR/Cas9-based approaches to create mutant and transgenic reporter zebrafish. These tools allow us to model and characterize human diseases, including neurodevelopmental and neurodegenerative disorders.

Defective neurotransmission is a hallmark of many disorders of the nervous system, including neurodegenerative diseases like Parkinson’s. Taking advantage of innovative genome editing techniques, we will develop zebrafish transgenic lines that express sensors of neurotransmitter activity (e.g Dopamine) in distinct subpopulations of neurons. These lines will be employed to detect and characterize the dynamics of neurotransmitter signaling in physiological and pathological conditions in vivo.

Publications

  • Publication 1: Jarque S, Ibarra J, Rubio-Brotons M, García-Fernández J, Terriente J. Multiplex Analysis Platform for Endocrine Disruption Prediction Using Zebrafish. Int J Mol Sci. 2019. Apr 8;20(7).

  • Publication 2: Pant DC, Dorboz I, Schlüter A, Fourcade S, Launay N, Joya J, Aguilera-Albesa S, Yoldi ME, Casasnovas C, Willis MJ, Ruiz M, Ville D, Lesca G, Siquier-Pernet K, Desguerre I, Yan H, Wang J, Burmeister M, Brady L, Tarnopolsky M, Cornet C, Rubbini D, Terriente J, James KN, Musaev D, Zaki MS, Patterson MC, Lanpher BC, Klee EW, Pinto E Vairo F, Wohler E, Sobreira NLM, Cohen JS, Maroofian R, Galehdari H, Mazaheri N, Shariati G, Colleaux L, Rodriguez D, Gleeson JG, Pujades C, Fatemi A, Boespflug-Tanguy O, Pujol A. Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy. J Clin Invest. 2019 Jan 8.

  • Publication 3: Cornet C, Di Donato V, Terriente J#. Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline. Front Pharmacol. 2018 Jul 3.